Vaccine最新文献

{"title":"Chimeric virus-like particles of nodavirus displaying M2e of human and avian influenza A viruses as a potential dual-use vaccine: Inducing a broader immune response and protecting mice against viral infections","authors":"Mohd Nasir Nurul Fatimah ,&nbsp;Bernard Yi Zhe Thian ,&nbsp;Chuan Loo Wong ,&nbsp;Hui Kian Ong ,&nbsp;Huzlinda Hussin ,&nbsp;Abdul Razak Mariatulqabtiah ,&nbsp;Kok Lian Ho ,&nbsp;Abdul Rahman Omar ,&nbsp;Wen Siang Tan","doi":"10.1016/j.vaccine.2025.127165","DOIUrl":"10.1016/j.vaccine.2025.127165","url":null,"abstract":"<div><div>The haemagglutinin (HA) and neuraminidase (NA) of influenza A viruses (IAVs) mutate rapidly, necessitating yearly updates to seasonal influenza vaccines. The highly conserved matrix 2 ectodomain protein (M2e) of IAVs presents a promising candidate for developing a universal influenza vaccine. However, variations in the M2e amino acid sequences, particularly in host-restriction specificity regions between human and avian IAVs, pose significant challenges. To broaden the M2e immunogenicity, we previously fused M2e from human and avian IAVs at the C-terminal end of <em>Macrobrachium rosenbergii</em> nodavirus capsid protein (NvC). The chimeric protein self-assembled into virus-like particles (VLPs), stimulating IgY antibodies and cell-mediated immune responses to human and avian M2e in chickens. In this study, we investigated the breadth and cross-subtype immunity of these chimeric VLPs in BALB/c mice to assess their potential for human use. The chimeric protein purified with immobilised metal affinity chromatography exhibited significant antigenicity to anti-H1N1 and anti-H9N2 M2e antibodies. Immunisation of BALB/c mice subcutaneously with the chimeric VLPs led to the development of anti-H1N1 and anti-H9N2 M2e-specific IgG antibodies that cross-reacted with M2e of H5N1 and H5N2 IAVs. The chimeric VLPs also elicited a strong cell-mediated immune response, characterised by a balanced Th1 and Th2 cytokine profile. Additionally, a significant increase in the CD8+/CD4+ cell ratio in splenocytes suggests enhanced cytotoxic T lymphocyte (CTL) activity. The chimeric VLPs, with or without adjuvant, conferred 100 % protection against challenges with four times median lethal dose (4xLD₅₀) of mouse-adapted H1N1 and H3N2 IAVs, reducing morbidity, pathology, and viral load in their lungs. Collectively, our data showed that the chimeric VLPs that induce potent immunogenicity in chickens hold potential for human application as demonstrated in BALB/c mice study, where anti-IAV immunity was broadened, protecting the mice from H1N1 and H3N2 IAV infections.</div></div>","PeriodicalId":23491,"journal":{"name":"Vaccine","volume":"56 ","pages":"Article 127165"},"PeriodicalIF":4.5,"publicationDate":"2025-04-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143869775","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Collaborative influenza vaccine innovation centers (CIVICs) program","authors":"Kentner L. Singleton ,&nbsp;Diane J. Post ,&nbsp;Alison D. Augustine ,&nbsp;Michael G. Ison","doi":"10.1016/j.vaccine.2025.127118","DOIUrl":"10.1016/j.vaccine.2025.127118","url":null,"abstract":"<div><div>N/A – Article type is Commentary.</div></div>","PeriodicalId":23491,"journal":{"name":"Vaccine","volume":"54 ","pages":"Article 127118"},"PeriodicalIF":4.5,"publicationDate":"2025-04-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143869650","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Corrigendum to ‘A randomised phase 2 immunogenicity and safety study of a MF59-adjuvanted quadrivalent subunit inactivated cell-derived influenza vaccine (aQIVc) in adults aged 50 years and older’ Vaccine 51 (2025) 126791","authors":"Brandon J. Essink ,&nbsp;Wim Vermeulen ,&nbsp;Coralie Andrade ,&nbsp;Richard de Rooij ,&nbsp;Leah Isakov ,&nbsp;Daniela Casula ,&nbsp;Frank R. Albano","doi":"10.1016/j.vaccine.2025.127127","DOIUrl":"10.1016/j.vaccine.2025.127127","url":null,"abstract":"","PeriodicalId":23491,"journal":{"name":"Vaccine","volume":"56 ","pages":"Article 127127"},"PeriodicalIF":4.5,"publicationDate":"2025-04-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143870066","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Safety and efficacy of a Vero-adapted live attenuated vaccine candidate for African swine fever","authors":"Tae-Young Suh ,&nbsp;Ji-Hoon Park ,&nbsp;Seong Yun Hwang ,&nbsp;Chae-Rin Park ,&nbsp;Ji-Eun Kim ,&nbsp;Jun Young Park ,&nbsp;Yong-Joo Kim ,&nbsp;Hae-Eun Kang ,&nbsp;Dae-Yong Kim ,&nbsp;Jun-Gu Choi","doi":"10.1016/j.vaccine.2025.127172","DOIUrl":"10.1016/j.vaccine.2025.127172","url":null,"abstract":"<div><div>African swine fever (ASF) is a lethal disease that significantly affects the global swine industry owing to the high mortality rate of infected pigs. The causative agent, ASF virus (ASFV), is difficult to control; however, live attenuated vaccines have recently emerged as a promising solution. This study evaluated the safety and efficacy of a novel live attenuated ASFV strain (VaCln3 P13) derived from a Korean ASFV isolate adapted to Vero cells. VaCln3 P13 harbors 12 non-synonymous SNPs across multiple viral genes without large gene deletions, all of which may collectively contribute to its attenuated phenotype. Notably, mutations in MGF300-2R and MGF505-7R result in protein truncation potentially influencing its safety. Our evaluation in domestic pigs inoculated with varying doses of VaCln3 P13, demonstrated substantial attenuation and protective efficacy against a virulent ASFV challenge, with only transient clinical signs and no severe adverse effects. All vaccinated pigs developed robust humoral immune responses and overcame the virulent parental virus challenge and survived, whereas mock-inoculated pigs succumbed within 10 days post-challenge. Pathological assessments revealed limited histopathological lesions in vaccinated pigs, while unvaccinated controls displayed extensive hemorrhage, lymphoid depletion, and severe systemic lesions after the challenge. These findings underscore the potential of VaCln3 P13 as a vaccine candidate for ASF control and hold promise for further applications.</div></div>","PeriodicalId":23491,"journal":{"name":"Vaccine","volume":"56 ","pages":"Article 127172"},"PeriodicalIF":4.5,"publicationDate":"2025-04-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143863916","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effectiveness of a single-dose mass dengue vaccination in Cebu, Philippines: Final results of a 5-year case-control study","authors":"Kristal An Agrupis ,&nbsp;Maria Vinna Crisostomo ,&nbsp;Jedas Veronica Daag ,&nbsp;Jesus Sarol Jr. ,&nbsp;March Helena Jane Lopez ,&nbsp;Kiarah Louise Florendo ,&nbsp;Clarissa de Guzman ,&nbsp;Ava Kristy Sy ,&nbsp;Zoraida Yurango ,&nbsp;Olivia Dandan ,&nbsp;Jean Balabat ,&nbsp;Jacqueline Deen ,&nbsp;Michelle Ylade","doi":"10.1016/j.vaccine.2025.127142","DOIUrl":"10.1016/j.vaccine.2025.127142","url":null,"abstract":"<div><h3>Background</h3><div>In mid-2017, the Philippine Department of Health launched a vaccination program of nine- to fourteen-year-old children using CYD-TDV (Dengvaxia, Sanofi) in Cebu province. The vaccination program was discontinued after only one dose was given. Until 2020, the interim vaccine effectiveness against hospitalized virologically confirmed dengue (VCD) and dengue with warning signs was 26 % and 51 %, respectively. In this report, we assess vaccine protection through February 2023.</div></div><div><h3>Methods</h3><div>From 15 February 2018 to 28 February 2023, we conducted a case-control study in Cebu province. Children residing in Cebu who were eligible to participate in the dengue mass vaccination in mid-2017 and subsequently admitted to any of four participating public hospitals with suspected dengue were enrolled. A blood sample was collected for dengue RT-PCR and clinical and socio-demographic information were obtained. Children hospitalized with VCD were followed until discharge and their illness classified according to WHO 2009 criteria as dengue, dengue with warning signs and severe dengue. To estimate the level of vaccine protection, vaccination status was compared between VCD cases and neighborhood controls of the same sex and age-group.</div></div><div><h3>Findings</h3><div>We included 584 VCD cases and 1168 controls in the analysis. Of the 584 cases, 397 (67·8 %) presented as dengue with warning sign (DWS), 8 (1·4 %) had severe dengue, and 1 (0·2 %) died. All four dengue virus serotypes were detected, but serotype 3 was the most common (287/584 or 49·1 %). Receipt of one dose of CYD-TDV was associated with 21 % (95 % CI, −7 to 41 %; <em>p</em> = 0·1129) overall protection against hospitalized VCD and 31 % (95 % CI, 6 to 49 %; <em>p</em> &lt; 0·0001) protection against more severe presentations of dengue (dengue with warning signs and severe dengue)<strong>.</strong></div></div><div><h3>Conclusion</h3><div>A single dose of CYD-TDV conferred extended protection against more severe presentations of dengue. The study is limited by an absence of baseline dengue serostatus of the participants prior to vaccination but a large majority in this this cohort were likely dengue seropositive.</div></div>","PeriodicalId":23491,"journal":{"name":"Vaccine","volume":"56 ","pages":"Article 127142"},"PeriodicalIF":4.5,"publicationDate":"2025-04-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143870065","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Testing an experimental vaccine during a public health emergency: Lessons from a Peruvian case","authors":"Claudio F. Lanata ,&nbsp;Theresa J. Ochoa ,&nbsp;Ernesto M. Bancalari ,&nbsp;Norman W. Baylor ,&nbsp;Kathryn Edwards ,&nbsp;Ruth R. Faden ,&nbsp;Shabir A. Madhi ,&nbsp;Hanna Nohynek ,&nbsp;Charles Weijer","doi":"10.1016/j.vaccine.2025.127176","DOIUrl":"10.1016/j.vaccine.2025.127176","url":null,"abstract":"<div><h3>Introduction</h3><div>The Peruvian Government searched for a vaccine as a response to COVID-19. A clinical trial evaluating an inactivated SARS-CoV-2 vaccine was approved. A national news program revealed that Peru's president had received the vaccine outside the clinical trial, generating a national protest. The Peruvian National Academy of Medicine created a commission to identify improper procedures and provide guidance on how to prevent a similar case in the future.</div></div><div><h3>Methods</h3><div>Commission members reviewed all publicly available documents and information sources and generated a final report.</div></div><div><h3>Results</h3><div>There were 6 ethical principles violations: 1) 3200 vaccine doses were used to vaccinate individuals outside the clinical trial; 2) prominent individuals were vaccinated outside of the clinical trial; 3) study conduct was monitored by a contract research organization with a conflict of interest; 4) an additional study was conducted with the vaccine without an approved protocol; 5) the placebo-controlled trial was continued when an approved vaccine was available; and 6) results of the clinical trial were not released.</div><div>There were 5 regulatory procedures ignored: 1) no clinical trial supervision by a high-quality clinical monitoring agency outside Peru; 2) a university acting as a sponsor of a vaccine produced by a foreign company; 3) expedited reviews and approvals; 4) lack of adequate supervision by local regulatory bodies and the study contract research organization (CRO); and 5) no input from the Data Safety Monitoring Board.</div></div><div><h3>Conclusions</h3><div>The COVID-19 health emergency created an environment where existing regulatory and ethical principles were circumvented under political pressure. Regulatory bodies and agencies should inform countries of the dangers of conducting clinical trials during a public health emergency and proper ethical and regulatory procedures should be followed.</div></div>","PeriodicalId":23491,"journal":{"name":"Vaccine","volume":"56 ","pages":"Article 127176"},"PeriodicalIF":4.5,"publicationDate":"2025-04-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143870062","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Optimization of the preparation method of inactivated intact virus particle vaccine for COVID-19","authors":"Marumi Ohno ,&nbsp;Toshiki Sekiya ,&nbsp;Richard Obeng-Kyeremeh ,&nbsp;Chimuka Handabile ,&nbsp;Minori Haruta ,&nbsp;Naoki Nomura ,&nbsp;Tomomi Kawakita ,&nbsp;Masashi Shingai ,&nbsp;Hiroshi Kida","doi":"10.1016/j.vaccine.2025.127173","DOIUrl":"10.1016/j.vaccine.2025.127173","url":null,"abstract":"<div><div>It has been recognized that it is difficult to maintain the virus particle structure of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which may be associated with lower immunogenicity of inactivated vaccines against coronavirus disease 2019 (COVID-19). We have previously demonstrated that an intact structure of the virus particles is critical for influenza inactivated whole virus particle vaccine (WPV) to be immunogenically potent. Here, we tested 37, 35, 33, and 31 °C for the virus propagation temperatures and the timing of formaldehyde treatment of the virus before and after centrifugation-based purification to obtain virus particles with an intact structure. Virus particles cultured at 33 °C retained spike proteins on the surface the most abundantly. The pretreatment of the virus with formaldehyde prevented the dissociation of the spike proteins from the viral surface during the centrifugation-based purification. The immunogenicity of the prepared vaccines, intact WPV and non-intact WPV that had lost the spike proteins, was evaluated in a mouse model. A single dose of intact WPV effectively induced humoral immunity compared to non-intact WPV, as indicated by higher titers of neutralizing antibodies. After a virus challenge, the mice vaccinated with a single dose of inactivated intact WPV showed less severe weight loss and lower virus titers in the lungs compared to those vaccinated with non-intact WPV. These results demonstrate the importance of the structural integrity of WPV in inducing effective and protective immunity, and provide significant insight into the development of COVID-19 WPV for practical use.</div></div>","PeriodicalId":23491,"journal":{"name":"Vaccine","volume":"56 ","pages":"Article 127173"},"PeriodicalIF":4.5,"publicationDate":"2025-04-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143870063","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Assessment of mpox awareness, attitudes, and vaccination intent among the United States public following an outbreak of mpox clade Ib in Africa.","authors":"Hannah Melchinger ,&nbsp;Maya Khemsara ,&nbsp;Noureen Ahmed ,&nbsp;Sameer M. Belgaumi ,&nbsp;Krutika Kuppalli ,&nbsp;Saad B. Omer ,&nbsp;Amyn A. Malik","doi":"10.1016/j.vaccine.2025.127141","DOIUrl":"10.1016/j.vaccine.2025.127141","url":null,"abstract":"<div><div>During the global outbreak of Clade IIb mpox (formerly known as monkeypox) in 2022, a survey of the US adult population (18+) found that knowledge of mpox and intention to vaccinate against it were low. Given the ongoing surge of Clade Ib in Africa, and recent reports of cases outside of Africa and in the US, we conducted a similar survey to assess whether US adult knowledge, attitudes, and practices towards mpox have changed since 2022. The survey, hosted by online survey company CloudResearch, asked questions about mpox awareness, risk perception, intention to vaccinate, and trusted sources of information. We found that 58% (95% CI 52–62) of US adults would be willing to receive the mpox vaccine if recommended by their doctor or health authority, a 12% increase from our 2022 results. Respondents from Health and Humans Services (HHS) Region 1 (CT, ME, MA, NH, RI, VT) were least likely to receive the vaccine, even if recommended to do so. Self-reported knowledge of mpox (40%), as well as perceived self-efficacy (55%) and mean risk perception (3.2) have also increased since the 2022 survey. Healthcare professionals remain the most trusted source of information (73%), and trust in the US government to provide accurate information has increased (58%). These results highlight the need for ongoing education among US adults to improve awarness of and vaccination intention for the mpox vaccine. The consistently high degrees of trust placed in healthcare professionals and officials should guide future communications about mpox and other infectious diseases, and reinforce the importance of leveraging trusted sources to share essential public health information.</div></div>","PeriodicalId":23491,"journal":{"name":"Vaccine","volume":"56 ","pages":"Article 127141"},"PeriodicalIF":4.5,"publicationDate":"2025-04-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143863774","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Understanding occupational and attitudinal factors influencing UK healthcare worker decisions for COVID-19 and influenza vaccination: A cross-sectional survey within SIREN","authors":"Quisha Bustamante ,&nbsp;Dominic Sparkes ,&nbsp;Lucy Findlater ,&nbsp;Katie Munro ,&nbsp;Irina Lut ,&nbsp;Jameel Khawam ,&nbsp;Sophie Russell ,&nbsp;Ana Atti ,&nbsp;Sarah Foulkes ,&nbsp;Susan Hopkins ,&nbsp;Victoria Hall ,&nbsp;Jasmin Islam","doi":"10.1016/j.vaccine.2025.127160","DOIUrl":"10.1016/j.vaccine.2025.127160","url":null,"abstract":"<div><h3>Background</h3><div>Seasonal vaccination of healthcare workers (HCWs) against COVID-19 and influenza has been recommended to protect patients and the workforce against Winter pressures. We aimed to investigate demographic, occupational, accessibility and tolerability factors associated with COVID-19 and influenza vaccination among HCWs within the SIREN study cohort in 2023/24.</div></div><div><h3>Methods</h3><div>We conducted a cross-sectional survey between 29 February-22 March 2024 within SIREN, a prospective HCW cohort across the UK. Adjusted odds ratios (aOR) and 95 % confidence intervals (CI) from a multivariable regression analysis were used to identify factors associated with vaccination. Proportions were calculated to describe the rationale for receiving/not receiving seasonal vaccines.</div></div><div><h3>Results</h3><div>A total of 5357/33,007 (16.2 %) SIREN participants completed the survey. 66.7 % (3572/5357) received both vaccines, 2.4 % (129/5357) COVID-19 only, 12.4 % (662/5357) influenza only, and 18.3 % (979/5357) neither. Participants were more likely to receive any vaccine if they were over 65 years (aOR 2.73, 95 % CI: 1.64–4.55), a doctor (aOR 2.28, 95 % CI: 1.70–3.05) or had a chronic respiratory condition (aOR 1.52, 95 % CI: 1.20–1.92). Participants of Black ethnicity were less likely to be vaccinated (aOR 0.42, 95 % CI: 0.27–0.66). The top reason for vaccination was to protect oneself (81.6 %). Concern about long-term side effects was the main reason for not getting vaccinated among those who did not receive the COVID-19 vaccine (30.1 %).</div></div><div><h3>Discussion</h3><div>We observed differences in uptake and attitudes towards seasonal vaccines among UK HCWs within the SIREN cohort. Differences in demographic characteristics, occupation and attitudes varied by vaccine type and this should be considered when planning seasonal vaccination programmes to protect the health workforce.</div></div>","PeriodicalId":23491,"journal":{"name":"Vaccine","volume":"56 ","pages":"Article 127160"},"PeriodicalIF":4.5,"publicationDate":"2025-04-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143870064","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Associations between parental vaccine hesitancy, religion-based vaccine hesitancy, and childhood full vaccination in a cross-sectional study in Aceh, Indonesia, 2023","authors":"Jacob Jacovetty ,&nbsp;Abram L. Wagner ,&nbsp;Ichsan Ichsan ,&nbsp;Amanda Yufika ,&nbsp;Tita Menawati ,&nbsp;Rosaria Indah ,&nbsp;Fitdha Kairadini ,&nbsp;Antonios M. Koumpias ,&nbsp;Harapan Harapan","doi":"10.1016/j.vaccine.2025.127154","DOIUrl":"10.1016/j.vaccine.2025.127154","url":null,"abstract":"<div><h3>Background</h3><div>Many Muslims in Indonesia have religion-based concerns surrounding vaccine ingredients. The aim of this study was to examine the correlation between parental religion-based vaccine hesitancy and other types of vaccine hesitancy, and to assess the association between parental vaccine hesitancy, religion-based vaccine hesitancy, and childhood full vaccination.</div></div><div><h3>Methods</h3><div>This study was based on a multistage, cluster sample within in Aceh, Indonesia. The survey included demographic characteristics, measures of vaccine hesitancy, structural barriers, and vaccination status questions. We examined correlations using Pearson correlation coefficient and the relationship between vaccine hesitancy, and religion-based vaccine concerns, on a child being fully vaccinated using a Poisson regression model with robust variance estimation.</div></div><div><h3>Results</h3><div>The study included 1689 participants and all were Muslim. Only 34 % of children were fully vaccinated, 29 % of parents were vaccine hesitant, and 32 % expressed concerns that vaccine ingredients were not halal. Childhood vaccination status, vaccine hesitancy, and religion-based concerns were all significantly correlated with each other. In a multivariable model, vaccine hesitancy and religion-based concerns were both directly significant in their relationship with childhood vaccination status. Those who were vaccine hesitant were only 0.21 times as likely to have a child fully vaccinated compared to those not hesitant (95 % CI: 0.16, 0.37). Those with concerns about vaccine ingredients being halal also were less likely to have a child fully vaccinated (PR: 0.55, 95 % CI: 0.42, 0.72).</div></div><div><h3>Conclusion</h3><div>We found that religious-based vaccine concerns were highly prominent in this population, and likely a large contributor to vaccine hesitancy. Efforts to improve vaccination coverage should focus on addressing religious concerns and working closely with religious leaders to build trust and disseminate accurate information about vaccines.</div></div>","PeriodicalId":23491,"journal":{"name":"Vaccine","volume":"56 ","pages":"Article 127154"},"PeriodicalIF":4.5,"publicationDate":"2025-04-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143863773","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}